5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Akums Drugs & Pharmaceuticals Ltd.

•
akums.inBSE: 544222NSE: AKUMS
Market Cap₹ 11,675 Cr.
Current Price
High / Low₹ 797 / 409
Stock P/E104.6
Book Value₹ 157
Price to Book2.94
Dividend Yield0.40 %
ROCE6.7 %
ROE4.7 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 3.14x)
  • Company has been maintaining a healthy dividend payout of 41.1%
  • Company comfortably covers its interest (15.8x coverage)
  • Institutional investors have been accumulating - FII+DII up 2.3pp

CONS

  • A large part of profit comes from other income (76.1% of PBT)
  • Recent results are weak - TTM profit is down 58.2% versus prior year
  • Company has a low return on equity of -18.3% over last 3 years
  • Operating cash flow has been negative in recent years
  • Company has a low return on capital employed of 1.0%
  • Promoter holding has decreased over last 2 years: -9.6pp

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.AKUMS741.7540.0211674.700.40100.9856.111166.6313.9314.7714.97
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
316447383298317328337329332309369338392
503358351359274285303311288292344327359
Operating Profit-1878932-61444334184417251233
OPM %-59.30%19.98%8.28%-20.29%13.77%13.12%10.09%5.39%13.27%5.46%6.70%3.48%8.47%
2042525263234322927262526
Interest4555642332232
Depreciation78899911101011121213
Profit before Tax-1788143-49546255376031362259
Tax %-6.36%34.85%32.47%-18.01%22.85%18.26%25.00%25.55%24.60%24.81%21.61%30.24%24.43%
Net Profit-1905329-58425041284523281545
-13.263.692.05-4.042.933.382.691.802.931.531.840.992.93

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
6285966837378371,1621,2871,4441,3121,3491,409
5995216016978111,5241,0891,5711,1771,2511,322
Operating Profit2975824027-362198-1271359787
OPM %4.68%12.63%11.99%5.42%3.19%-31.15%15.38%-8.77%10.26%7.23%6.15%
43555766-19558-475128106104
Interest5344141318151010
Depreciation2423232526283033404648
Profit before Tax4310511276-195-335150-103208148148
Tax %25.27%35.32%33.21%32.95%25.50%-13.97%16.56%-60.74%22.54%24.75%24.68%
Net Profit32687551-145-382125-165161112112
EPS276.00580.00636.00391.04-20.33-26.698.77-11.5610.527.29—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%41.14%—

COMPOUNDED SALES GROWTH

10 Years:
9%
5 Years:
10%
3 Years:
2%

COMPOUNDED PROFIT GROWTH

10 Years:
10%
5 Years:
—
3 Years:
-4%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
60%

RETURN ON EQUITY

10 Years:
-10%
5 Years:
-21%
3 Years:
-18%
Last Year:
5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jul 3

₹ 0.50

Rs.1.0000 per share(50%)Final Dividend

2026

Jul 3

₹ 1

Rs.2.0000 per share(100%)Special Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital111111429293131
6987668417115661712831152,2752,397
4937555436011,1941,2831,6335470
Trade Payables43866910890252178165220201
697181627182119154106113
Total Liabilities8609601,0461,4261,2651,8141,8912,0952,6852,812
227219220226229233253298338407
Capital Work in Progress0001111695452
44465149141139139366366
8812110612396179197162202230
0000000234206218
Cash & Bank30472126973356771
5386157129387881,2341,2771,1811,164770
Total Assets8609601,0461,4261,2651,8141,8912,0952,6852,812

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
539237256023612424891-2
Cash from Investing-35-46-15-242-100-298-202-165-459-25
Cash from Financing-8-281530239590-21375-3
1-2338-4225-18628-30

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Mar 2023Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
84.9175.2675.2675.2675.2675.2675.2675.2675.26
0.007.346.365.774.242.271.141.381.91
0.007.256.717.398.859.2814.4114.3613.44
Government0.000.000.000.000.000.000.000.000.00
15.0910.1611.6611.5811.6613.199.199.029.39

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-03
General Updates

2026-09-03 - Intimation of ESG Rating

2026-08-25
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-25 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-24
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-24 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about an Update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026

2026-08-13
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-13 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-13
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-13 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript

2026-08-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Link of Recording

2026-08-10
Copy of Newspaper Publication

2026-08-10 - Copy of Newspaper Publication

2026-08-10
Monitoring Agency Report

2026-08-10 - Monitoring Agency Report for the quarter ended June 30, 2026

News

Recent coverage and analyst commentary for AKUMS

Loading news…

🤖

AI Stock Analyst

Akums Drugs & Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login